Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer ' s disease

This guidance updates and replaces NICE technology appraisal guidance 111 issued in November 2006 (amended September 2007, August 2009). The review and re-appraisal of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer ' s disease has resulted in a change in the guidance. Specifically: donepezil, galantamine and rivastigmine are now recommended as options for managing mild as well as moderate Alzheimer ' s disease, and memantine is now recommended as an option for managing moderate Alzheimer ' s disease for people who cannot take AChE inhibitors, and as an option for managing severe Alzheimer ' s disease.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news